Measuring productivity loss in early relapsing-remitting multiple sclerosis
Por:
de la Maza, S, Maurino, J, Borges, M, Martin-Martinez, J, Sotoca, J, Alonso, A, Caminero, A, Borrega, L, Sanchez-Menoyo, J, Barrero-Hernandez, F, Calles, C, Brieva, L, Blasco, M, Garcia-Soto, J, del Campo-Amigo, M, Navarro-Canto, L, Aguera, E, Garces, M, Carmona, O, Gabaldon-Torres, L, Forero, L, Hervas, M, de Alda, L, Gomez-Ballesteros, R and Castillo-Trivino, T
Publicada:
1 feb 2022
Ahead of Print:
1 feb 2022
Resumen:
Background: Multiple sclerosis is one of the most common causes of neurological disability in young adults with major consequences for their autonomy and capacity to maintain employment.
Objective: The aim of this study was to assess the impact on work productivity in early-stage relapsing-remitting multiple sclerosis (RRMS).
Methods: A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS, a disease duration <= 3 years, and an Expanded Disability Status Scale (EDSS) score of 0-5.5 were included. Absenteeism, presenteeism, and unpaid work loss due to RRMS were measured using the Valuation of Lost Productivity (VOLP) questionnaire. The EDSS, SymptoMScreen, 5-item Modified Fatigue Impact Scale, Hospital Anxiety and Depression Scale, Symbol Digit Modalities Test, and Multiple Sclerosis Work Difficulties Questionnaire were used to gather information on disability, patients' perception of symptom severity, fatigue, mood/ anxiety, cognition, and problems in the workplace, respectively. Associations between the VOLP and clinical and work outcomes were analyzed using Spearman's rank correlations.
Results: A total of 189 patients were included. Mean age (SD) was 36.1 +/- 9.4 years and 71.4% were female. Mean disease duration was 1.2 +/- 0.8 years. Median EDSS score was 1.0 (IQR 0, 2.0). One hundred thirty patients (68.8%) were working for pay or self-employed. Fifty-three patients (40.8%) reported absence from work in the past 3 months with an average of 14.3 absent workdays. Their health problems resulted in the loss of 3.4% of their actual work time in the past 7 days. Thirty patients got help (11.8 h) with their unpaid work activities in the past 7 days. Absenteeism was significantly correlated with anxiety and depression (rho=0.298 and 0.291, p < 0.001), fatigue (rho=0.214, p = 0.014), and symptom severity (rho=0.213, p = 0.015). Presenteeism was significantly correlated with fatigue (rho=0.375,p < 0.001), symptom severity (rho=0.373, p < 0.001), depression (rho=0.263, p = 0.008), and disability (rho=0.215, p = 0.031).
Conclusions: Productivity loss even in a RRMS population with short disease duration stresses the need for more efficient treatment control of disease activity from earlier stages.
Filiaciones:
de la Maza, S:
Hosp Univ Ramon y Cajal, Dept Neurol, Madrid, Spain
Maurino, J:
Roche Farma, Med Dept, Madrid, Spain
Borges, M:
Hosp Univ Virgen Macarena, Dept Neurol, Seville, Spain
Martin-Martinez, J:
Hosp Univ Miguel Servet, Dept Neurol, Zaragoza, Spain
Sotoca, J:
Hosp Univ MatuaTerrassa, Dept Neurol, Barcelona, Spain
Alonso, A:
Hosp Reg Univ Malaga, Dept Neurol, Malaga, Spain
Caminero, A:
Complejo Asistencial Avila, Dept Neurol, Avila, Spain
Borrega, L:
Hosp Univ Fdn Alcorcon, Dept Neurol, Alcorcon, Spain
Sanchez-Menoyo, J:
Hosp Galdakao Usansolo, Dept Neurol, Galdakao, Spain
Barrero-Hernandez, F:
Hosp Univ Clin San Cecilio, Dept Neurol, Granada, Spain
Calles, C:
Hosp Univ Son Espases, Dept Neurol, Palma De Mallorca, Spain
Brieva, L:
Hosp Arnau Vilanova, Dept Neurol, Lleida, Spain
Blasco, M:
Hosp Univ Puerta Hierro, Dept Neurol, Madrid, Spain
Garcia-Soto, J:
Hosp Univ Virgen Macarena, Dept Neurol, Seville, Spain
del Campo-Amigo, M:
Complexo Hosp Univ Pontevedra, Dept Neurol, Pontevedra, Spain
:
Hosp Gen Univ Elche, Dept Neurol, Elche, Spain
Aguera, E:
Hosp Univ Reina Sofia, Dept Neurol, Cordoba, Spain
Garces, M:
Hosp Clin Univ Lozano Blesa, Dept Neurol, Zaragoza, Spain
Carmona, O:
FundaciO Salut Emporda, Dept Neurol, Figueres, Spain
:
Hosp Francesc de Borja, Dept Neurol, Gandia, Spain
Forero, L:
Hosp Univ Puerta del Mar, Dept Neurol, Cadiz, Spain
Hervas, M:
Consorci Corp Sanitaria Parc Tauli, Dept Neurol, Sabadell, Spain
de Alda, L:
Roche Farma, Hlth Econ & Outcomes Res Unit, Madrid, Spain
Gomez-Ballesteros, R:
Roche Farma, Med Dept, Madrid, Spain
Castillo-Trivino, T:
Hosp Univ Donostia, Dept Neurol, San Sebastian, Spain
|